Bowhead Specialty (NYSE:BOW - Get Free Report) had its target price hoisted by Morgan Stanley from $30.00 to $34.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has an "equal weight" rating on the stock. Morgan Stanley's price objective would suggest a potential upside of 1.57% from the company's previous close.
Several other research firms have also recently weighed in on BOW. Royal Bank Of Canada cut Bowhead Specialty from an "outperform" rating to a "sector perform" rating and reduced their price objective for the stock from $38.00 to $34.00 in a research report on Tuesday, August 4th. Piper Sandler lowered Bowhead Specialty from an "overweight" rating to a "hold" rating and set a $34.00 target price on the stock. in a research report on Monday, August 3rd. Keefe, Bruyette & Woods boosted their target price on Bowhead Specialty from $34.00 to $36.00 and gave the company an "outperform" rating in a research note on Wednesday, July 8th. Weiss Ratings raised Bowhead Specialty from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday, June 23rd. Finally, Deutsche Bank Aktiengesellschaft cut shares of Bowhead Specialty from a "buy" rating to a "hold" rating and set a $34.00 price target for the company. in a research note on Monday, August 3rd. Two analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $33.50.
Get Our Latest Stock Report on BOW
Bowhead Specialty Trading Up 0.1%
Shares of NYSE:BOW opened at $33.48 on Wednesday. Bowhead Specialty has a 12 month low of $21.21 and a 12 month high of $35.07. The company has a quick ratio of 0.49, a current ratio of 0.49 and a debt-to-equity ratio of 0.31. The company's fifty day simple moving average is $30.76 and its 200 day simple moving average is $26.82. The firm has a market cap of $1.10 billion, a price-to-earnings ratio of 18.09, a PEG ratio of 1.00 and a beta of -0.11.
Bowhead Specialty (NYSE:BOW - Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported $0.48 earnings per share for the quarter, topping analysts' consensus estimates of $0.47 by $0.01. The firm had revenue of $163.86 million during the quarter, compared to analyst estimates of $278.69 million. Bowhead Specialty had a net margin of 10.11% and a return on equity of 14.05%. As a group, research analysts forecast that Bowhead Specialty will post 1.99 EPS for the current fiscal year.
Institutional Trading of Bowhead Specialty
Institutional investors and hedge funds have recently bought and sold shares of the business. Langdon Equity Partners bought a new position in shares of Bowhead Specialty during the 4th quarter worth approximately $28,000. Versant Capital Management Inc raised its stake in Bowhead Specialty by 262.6% in the 2nd quarter. Versant Capital Management Inc now owns 1,037 shares of the company's stock valued at $31,000 after acquiring an additional 751 shares during the period. Parallel Advisors LLC lifted its holdings in Bowhead Specialty by 181.4% during the 1st quarter. Parallel Advisors LLC now owns 1,652 shares of the company's stock valued at $37,000 after purchasing an additional 1,065 shares during the last quarter. CWM LLC lifted its holdings in Bowhead Specialty by 257.7% during the 4th quarter. CWM LLC now owns 1,481 shares of the company's stock valued at $42,000 after purchasing an additional 1,067 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in Bowhead Specialty during the second quarter worth $52,000.
Bowhead Specialty Company Profile
(
Get Free Report)
Bowhead Specialty Holdings Inc provides specialty property and casualty insurance products in the United States. It underwrites casualty insurance solutions for risks in the construction, distribution, heavy manufacturing, real estate, and hospitality segments; professional liability insurance solutions for financial institutions, private and public directors and officers liability insurance, errors and omissions liability insurance, and cyber segments; and healthcare solutions for hospitals, senior care providers, managed care organizations, miscellaneous medical facilities, and healthcare management liability segments.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Bowhead Specialty, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bowhead Specialty wasn't on the list.
While Bowhead Specialty currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.